Introduction
Daptomycin is a novel cyclic lipopeptide agent that is currently being reassessed for the treatment of infections caused by Gram-positive pathogens. It is bactericidal against susceptible and resistant Gram-positive bacteria, including MRSA, VRE, MRSE, PRSP and GISA strains. One feature of daptomycin not found to such a marked degree in other antimicrobials is the dependence of its activity upon physiological concentrations of calcium ions in the medium. 1, 2 The mechanism is unknown but possibly related to the divalent ion being required for drug attachment or penetration into the bacterial cell. It has been recommended that a concentration of 50 mg/L of Ca 2ϩ be present to accurately test the activity. 2 This accords with the physiological free Ca 2ϩ concentration of 1.15-1.31 mM found in plasma. 3 This study compared the in vitro activity of daptomycin (with and without a 50 mg/L Ca 2ϩ supplement) with that of other agents commonly used to treat Gram-positive infections. In addition, a study to establish a tentative breakpoint between resistant and susceptible pathogens, which should be of use in the clinical laboratory, was undertaken.
Materials and methods
A total of 328 Gram-positive organisms were studied, the majority of which were recent clinical isolates. The remainder were strains with well-characterized resistance mechanisms. The following agents were employed: daptomycin (Cubist Pharmaceutical Inc., Boston, MA, USA), vancomycin (Lilly Products, Basingstoke, UK), quinupristin/ dalfopristin and teicoplanin (Aventis Pharmaceutical, Denham, UK), gemifloxacin and co-amoxiclav (GlaxoSmithKline, Worthing, UK) and linezolid (Pharmacia, Milton Keynes, UK).
Susceptibilities were determined by a standard agar plate dilution method following the recommendations of Oliver et al. 4 Briefly, isotonic sensitivity test agar (pH 7.2) (Mast, Bootle, UK) was employed, both alone and supplemented to 50 mg/L Ca 2ϩ . For streptococci, 5% defibrinated horse blood was also added. All strains were tested at a final inoculation of 10 4 cfu using a multipoint inoculator (Denley Instruments, Billinghurst, UK). Plates were incubated at 37ЊC for 18-24 h in air (except for Streptococcus pneumoniae and Streptococcus milleri, which were incubated in 4-6% CO 2 in air). Co-amoxiclav estimations employed amoxicillin and clavulanate in a 2:1 ratio with the result recorded in terms of the amoxicillin concentration. The effect of serum on the MIC and minimum bactericidal concentration (MBC) of daptomycin was studied for two strains each of Streptococcus pyogenes, S. pneumoniae, Enterococcus faecium (including one vancomycin resistant strain) and two methicillin susceptible Staphylococcus aureus strains. An agar dilution (as described above) and a broth microdilution method were compared. The micro- 5 cfu/mL. The MIC was defined as the lowest concentration at which there was no visible growth. Following incubation, 100 L of broth was subcultured on to appropriate antibiotic-free media for MBC determination. The MBC was defined as the lowest antibiotic concentration to show no growth (99.9% kill).
Disc susceptibility testing was undertaken on the same media utilizing the same organisms as noted above. The inoculum was adjusted to yield semi-confluent growth. Plates were incubated under the same conditions as above following the application of 30 g daptomycin discs. The zone sizes were recorded following overnight incubation, as above.
Results
The activity of daptomycin against the Gram-positive pathogens tested is shown in the Table. The addition of Ca 2ϩ to the media to physiological concentrations of 50 mg/L had a marked effect on all species tested. The MIC 90 was eight-to 16-fold lower in the presence of Ca 2ϩ , the only exception being Staphylococcus saprophyticus where the decrease in MIC 90 was four-fold. Further discussion of the results will refer to those obtained with the calcium supplement.
The addition of calcium did not affect the susceptibilities of the other agents studied by more than one dilutional step.
All S. aureus, both methicillin susceptible and resistant, were inhibited by 0.5 mg/L or less of daptomycin. Similar results were obtained for quinupristin/dalfopristin. All strains of S. epidermidis and S. saprophyticus were inhibited by 1 mg/L or less of daptomycin and quinupristin/ dalfopristin was more active (all strains inhibited by 0.5 mg/L). All strains of Staphylococcus spp. tested were susceptible to р2 mg/L of linezolid.
E. faecalis and E. faecium were equally susceptible to the daptomycin plus Ca 2ϩ , with all the MICs being р4 mg/L and the MIC 90 2 mg/L, whereas the strains of E. faecalis were 16-fold less susceptible to quinupristin/dalfopristin than the strains of E. faecium and four strains of E. faecalis were resistant to vancomycin (MIC Ͼ 8 mg/L). All these strains were as susceptible to daptomycin and linezolid as the vancomycin susceptible population. Co-amoxiclav and gemifloxacin had activity against E. faecalis but E. faecium strains were markedly less susceptible. All the agents studied displayed good activity against S. pneumoniae. Twentyfour strains were less susceptible to co-amoxiclav (MIC у1 mg/L) but these were as susceptible to daptomycin, gemifloxacin, linezolid and the glycopeptides as the coamoxiclav susceptible strains. Two strains of S. pneumoniae were resistant to quinupristin/dalfopristin (MICs 16 mg/L) but no decrease in susceptibility was noted against the other agents. S. milleri, 20 Lancefield group A and 20 group B strains were all susceptible to р1 mg/L of daptomycin. Human serum had little effect on the activity of daptomycin. In broth there was very little difference between the MIC and the MBC and results in broth mirrored those in agar. The MIC in the presence of serum tended to show a single dilution step increase when compared with that in broth. There was a more marked effect on the MBC.
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In order to establish a zone diameter breakpoint, the MIC determined for each strain was plotted against the zone diameter obtained for the 30 g daptomycin disc ( Figure) . Using a zone diameter breakpoint of у20 mm to denote susceptibility, no false resistance was observed and a false susceptibility rate of 0.61% was found (which consisted of two strains of E. faecium).
Discussion
The mode of action of daptomycin is poorly understood. The target is thought to be the cytoplasmic membrane and a disruption of the electrical potential across this membrane has been described, as have putative daptomycin binding proteins at this site. 4 These authors also report very low frequencies (Ͻ10 -10 ) of spontaneous resistance in S. aureus. The in vitro activity of this compound is highly dependent upon the calcium ion content of the culture medium 5, 6 yet the mechanism underlying this observation is poorly understood and it has been thought that Ca 2ϩ may aid penetration of the bacterial membrane. 2 We confirm the observation of enhanced activity in the presence of the cation; 2, 5, 6 the earlier reports employed Mueller-Hinton agar, whereas we used an isotonic medium of the type more commonly employed in Europe. An eight-to 16-fold reduction in the MIC was generally observed when Ca 2ϩ was added compared with the unsupplemented medium.
As the physiological concentration of calcium in the body is 45-55 mg/L, 3 this calcium dependence is an important testing issue.
The protein binding of daptomycin has been reported as 92% (B. Dvorchik, personal communication). As would be expected, there is a moderate effect upon the antimicrobial in the presence of human serum, the MIC increasing twoto four-fold and the MBC four-to eight-fold.
The tentative breakpoint of 2 mg/L of daptomycin was derived from the knowledge of the pharmacokinetics of the agent. Following a 4 mg/kg dose, a mean C max of c. 70 mg/L is attained. 7 Application of the BSAC breakpoint formula 8 would suggest a breakpoint of c. 4-8 mg/L. As so few strains had an MIC Ͼ 2 mg/L it was considered reasonable to choose a lower figure, which still yielded satisfactory results. The results we obtained are, naturally, somewhat different from those described by Fuchs et al., 6 who employed the NCCLS methodology, but equally reproducible. We did not believe that an 'intermediate' designation of susceptibility was appropriate.
These studies suggest that daptomycin should be a valuable addition to the agents available to treat infections caused by Gram-positive pathogens. The results of clinical trials are awaited to confirm this view and to assess the suitability of the proposed tentative breakpoint.
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Figure.
Scattergram analysis for 328 strains tested for susceptibility using daptomycin disc (30 g) and media containing 50 mg/L Ca 2ϩ . Numbers indicate the numbers of strains represented at each point.
